New combo therapy aims to control multiple myeloma after first return
NCT ID NCT06252792
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at a drug combination (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has come back for the first time. The goal is to see how well it controls the cancer and delays further progression. About 50 adults will take part, and the study will compare this treatment to other standard options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIRST RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact